Treatment of atypical hemolytic uremic syndrome with eculizumab in a patient presenting with neuropsychiatric prodrome: a case report
Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy (TMA) caused by dysregulation of the complement system. It is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Owing to its diverse and nonspecific clinical manifestations, ea...
Saved in:
| Main Authors: | Hanze Yang, Jingdong Zhang, Hao Wu, Hongzhao Xu, Zhonggao Xu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1542973/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
“Eculizumab First” in the Management of Posttransplant Thrombotic Microangiopathy
by: Federica Maritati, et al.
Published: (2024-04-01) -
Atypical Hemolytic Uremic Syndrome Triggered by COVID‐19 Infection in a Pediatric Patient With CD46 Mutation
by: Parsa Lorestani, et al.
Published: (2025-03-01) -
Difficulties in diagnosing atypical hemolytic uremic syndrome
by: N. V. Fomina, et al.
Published: (2020-01-01) -
SUCCESSFUL TREATMENT FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME IN A PUERPERA
by: O. N. Ulitkina, et al.
Published: (2016-01-01) -
Difficulties in diagnostics of atypical hemolytic uremic syndrome in the intensive care unit
by: N. L. Kozlovskаya, et al.
Published: (2019-09-01)